PABLO DE LA
CUEVA DOBAO
Profesor asociado de Ciencias de la Salud
Hospital General Universitario de Valencia
Valencia, EspañaPublications in collaboration with researchers from Hospital General Universitario de Valencia (20)
2024
2023
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology
-
Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results
Journal of Investigational Allergology and Clinical Immunology
2022
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572
2021
-
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
-
Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis
Journal of the European Academy of Dermatology and Venereology, Vol. 33, Núm. 7, pp. 1214-1223
-
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
Journal of Dermatological Treatment, Vol. 29, Núm. 4, pp. 334-346
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis
Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602
-
Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations
Actas dermo-sifiliograficas, Vol. 107, Núm. 3, pp. 194-206
-
Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations
Actas Dermo-Sifiliograficas, Vol. 107, Núm. 3, pp. 194-206
-
Urine metabolome profiling of immune-mediated inflammatory diseases
BMC Medicine, Vol. 14, Núm. 1
2015
-
A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk
Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881
-
Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis
Pharmacogenomics Journal, Vol. 15, Núm. 4, pp. 322-325